secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001798749-24-000029
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aerovate reports Q1 2024 net loss $23.2M; cash $99.3M; Phase 2b topline data expected June 2024
--------------------------------------------------------------------------------

- Net loss of $23.2M for Q1 2024 vs $16.5M in Q1 2023; R&D expenses $20.1M, G&A $4.5M.
- Cash, equivalents and short-term investments $99.3M at March 31, 2024; raised net $23.6M via ATM in April.
- Topline data from Phase 2b portion of IMPAHCT trial of AV-101 in PAH expected in June 2024.
- Enrollment continues in Phase 3 portion of IMPAHCT; over 120 sites in 20+ countries.
- Cash runway into 2026 based on current operating plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000179874924000029/0001798749-24-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000179874924000029/tmb-20240513x8k.htm
  HTML page:      https://secwatch.observer/filing/0001798749-24-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer